We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Presepsin Concentrations Correlate with Kidney Function Decline

By LabMedica International staff writers
Posted on 24 Oct 2019
Sepsis is an important public health problem with more than 750,000 patients reported yearly in the USA with similar figures in Europe. More...
Sepsis continues to be a challenge for practitioners, as sepsis mortality rates are still high despite new antimicrobial and resuscitation agents.

Chronic kidney disease (CKD) is a worldwide health problem and its prevalence is rising, particularly in the elderly, mainly reflecting the increased life expectancy of the global population. The plasma presepsin concentrations of healthy individuals are very slight, but have been shown to increase in response to bacterial infections according to disease severity.

Medical scientists at the Nippon Medical School (Tokyo, Japan) and their colleagues enrolled CKD patients aged ≥65 years who had visited a nephrology outpatient department between April 2015 and March 2016. The median age of patients of this cohort was 77.8 (72-85) years and the mean estimated glomerular filtration rate (eGFR) was 51.8 ± 28.1 mL/min/1.73m2.

Serum creatinine was measured in serum specimens using an automated enzymatic method. Normal values of serum creatinine are <1.1 mg/dL for men and 0.7 mg/dL for women. Serum cystatin C was measured using a particle-enhanced immunonephelometric assay with the Siemens BN ProSpec nephelometer. C-reactive protein (CRP) was measured by latex-enhanced immunonephelometric assay with the Siemens BN ProSpec nephelometer.

Plasma presepsin concentrations were measured using an automated immunoassay analyzer based on noncompetitive chemiluminescent enzyme immunoassay. The relationship between plasma presepsin concentration and kidney function was assessed. eGFRcr, eGFRcys, CKD-EPI eGFRcr-cys were used to classify patients by GFR stage (G1-G5).

The scientists reported that plasma presepsin concentrations in those with CKD G4-G5 (362 pg/mL [273-553]) were significantly higher than in those with CKD G1-G2 (111 pg/mL [91-113]) and CKD G3 (145 pg/mL [124-205]). A high correlation between plasma presepsin concentrations and kidney function was observed. Even after adjusting for confounders, plasma presepsin concentrations were independently associated with kidney function.

The authors concluded that they had found that increases in plasma presepsin concentrations were exponentially correlated to decline in kidney function in the elderly with CKD. Prediction of plasma presepsin concentrations through commensurate decline in kidney function in the elderly should help in the precise diagnosis of sepsis in clinical practice. The study was published on October 5, 2019, in the journal Clinica Chimica Acta.

Related Links:
Nippon Medical School


Gold Member
Immunochromatographic Assay
CRYPTO Cassette
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Sperm Quality Analyis Kit
QwikCheck Beads Precision and Linearity Kit
Gram-Negative Blood Culture Assay
LIAISON PLEX Gram-Negative Blood Culture Assay
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: AI-powered ctDNA analysis provides clinicians with a new lens to monitor disease evolution (Photo courtesy of Brandon Stelter, Katie Han, Kyle Smith, and Paul Northcott)

AI-Powered Liquid Biopsy Classifies Pediatric Brain Tumors with High Accuracy

Liquid biopsies offer a noninvasive way to study cancer by analyzing circulating tumor DNA in body fluids. However, in pediatric brain tumors, the small amount of ctDNA in cerebrospinal fluid has limited... Read more

Immunology

view channel
Image: The TmS computational biomarker analyzes tumor gene expression and microenvironment data to guide treatment decisions (Photo courtesy of MD Anderson Cancer Center)

New Biomarker Predicts Chemotherapy Response in Triple-Negative Breast Cancer

Triple-negative breast cancer is an aggressive form of breast cancer in which patients often show widely varying responses to chemotherapy. Predicting who will benefit from treatment remains challenging,... Read more

Pathology

view channel
Image: Sophie Paczesny, M.D., Ph.D and her team have made BIOPREVENT freely available for researchers and clinician to test and learn from (Photo courtesy of Cliff Rhodes)

AI Tool Uses Blood Biomarkers to Predict Transplant Complications Before Symptoms Appear

Stem cell and bone marrow transplants can be lifesaving, but serious complications may arise months after patients leave the hospital. One of the most dangerous is chronic graft-versus-host disease, in... Read more

Industry

view channel
Image: QuidelOrtho has entered into a strategic supply agreement with Lifotronic to expand its global immunoassay portfolio (Photo courtesy of QuidelOrtho)

QuidelOrtho Collaborates with Lifotronic to Expand Global Immunoassay Portfolio

QuidelOrtho (San Diego, CA, USA) has entered a long-term strategic supply agreement with Lifotronic Technology (Shenzhen, China) to expand its global immunoassay portfolio and accelerate customer access... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.